Weekly Investment Analysts’ Ratings Updates for Eli Lilly and Company (LLY)

Several brokerages have updated their recommendations and price targets on shares of Eli Lilly and Company (NYSE: LLY) in the last few weeks:

• 6/25/2026 – Eli Lilly and Company had its price target raised by Leerink Partners from $1,119.00 to $1,232.00. They now have an “outperform” rating on the stock.
• 6/22/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/22/2026 – Eli Lilly and Company had its price target raised by Berenberg Bank from $1,050.00 to $1,135.00. They now have a “hold” rating on the stock.
• 6/15/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
• 6/9/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,330.00 to $1,350.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein.
• 6/5/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley.
• 5/26/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,133.00 to $1,251.00. They now have a “buy” rating on the stock.
• 5/26/2026 – Eli Lilly and Company was given a new $1,119.00 price target by Leerink Partners.
• 5/22/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $1,283.00 price target on the stock.
• 5/21/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Wolfe Research. They now have a $1,350.00 price target on the stock.
• 5/21/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 5/21/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,300.00 to $1,330.00.
• 5/19/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 5/7/2026 – Eli Lilly and Company had its price target raised by Rothschild & Co Redburn from $880.00 to $900.00.
• 5/5/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Guggenheim. They now have a $1,183.00 price target on the stock.
• 5/4/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 5/4/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Wolfe Research. They now have a $1,325.00 price target on the stock.
• 5/4/2026 – Eli Lilly and Company had its price target raised by Barclays PLC from $1,350.00 to $1,400.00. They now have an “overweight” rating on the stock.
• 5/2/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $1,344.00 price target on the stock.
• 5/1/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 5/1/2026 – Eli Lilly and Company had its price target lowered by Bank of America Corporation from $1,294.00 to $1,133.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,205.00 to $1,230.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target raised by The Goldman Sachs Group, Inc. from $1,260.00 to $1,283.00. They now have a “buy” rating on the stock.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.